A ‘new’ type of vaccine is being developed using artificial intelligence (AI). A team of researchers from the University of Cambridge recently claimed that this vaccine would provide protection against various types of viruses and help prevent future pandemics.

The researchers stated that this is the first time the core components of a vaccine have been designed entirely using AI. Preliminary trials on humans have already been conducted.

The vaccine is designed to be effective against all types of coronaviruses. This includes not only the known variants affecting humans but also viruses found in animals that could potentially trigger future pandemics in the human population.

Although the research is still in its early stages, the Cambridge team has already begun working on separate vaccines for influenza and Ebola using AI.

How ​​It Works

Vaccines essentially teach our bodies to recognize pathogens, enabling the immune system to fight off viruses more effectively. However, some viruses mutate—or change their form—rapidly. Due to these mutations, vaccines can quickly lose their effectiveness, which is why vaccines for coronavirus and seasonal flu require regular updates.

— Jonathan Heeney, Professor, University of Cambridge

“We are always lagging behind the virus; our goal is to stay one step ahead,” says Professor Jonathan Heeney of the University of Cambridge. They aim to stay far enough ahead to prevent a new pandemic before it even begins. While vaccines are typically developed based on existing viral strains, the Cambridge researchers have adopted a different approach.

They collect genetic codes from various coronaviruses identified through surveillance programs. Artificial intelligence then analyzes these genetic codes.

Subsequently, the AI ​​generates a ‘super-antigen.’ This antigen—a type of protein—primes the human immune system to provide protection against all the relevant viral strains. The vaccine remains effective even if the virus mutates. It would even provide protection against new viruses jumping from animals to humans.

The most crucial component of a vaccine is the antigen, as it is what teaches our immune system to recognize and attack the enemy—the virus.

Professor Heeney stated that this marks the first time an AI-designed antigen has been tested in humans. This technology is astonishing everyone and holds great promise for the benefit of humanity.

The Cambridge professor told BBC News, “The goal of this vaccine is not merely to protect against current viruses but to safeguard us against future pandemics. It represents a major shift in pandemic preparedness.”
Human Trials

Initial trials were conducted on 39 people to assess the vaccine’s safety. A second trial involving approximately 200 people will follow, which will help determine how effectively it boosts the human immune system.

Andy Pollard, Director, Oxford Vaccine Group

The research findings were published in the Journal of Infection, a reputable medical journal. The study indicates that while the impact on the immune system is currently “moderate,” researchers remain highly optimistic.

Professor Saul Faust from the University of Southampton in the UK was involved in the trial. He remarked, “There is no doubt about the potential of this AI-driven design; it is truly remarkable. This technology is particularly effective for developing pandemic vaccines when dealing with viruses that mutate rapidly.”

The Cambridge team is currently conducting animal studies for a universal flu vaccine. If successful, this vaccine would eliminate the need for annual vaccinations. They are also working on a vaccine for the H5N1 bird flu.

Additionally, the team is attempting to develop a vaccine for viral hemorrhagic fevers, a category that includes Ebola. There is currently no vaccine available for the specific strain of the fever spreading in the Democratic Republic of the Congo.

Professor Andy Pollard, Director of the Oxford Vaccine Group, was not involved in this research. Speaking to BBC News about this AI-designed vaccine, he noted that research on animals has yielded promising evidence for the technology, describing it as excellent news.

However, Pollard observed, “The human immune system differs from that of laboratory mice. Our immune systems are shaped over years of exposure to various infections. Therefore, the true test will be the outcome of human trials.”

Pollard added that, overall, artificial intelligence is set to transform the landscape of vaccine research, enabling faster vaccine development and the potential to save many lives.

Professor Marian Knight, Scientific Director at the UK’s National Institute for Health and Care Research, stated that the success of this AI-designed trial marks a significant step toward achieving long-lasting protection against the virus.

UK Science Minister Lord Vallance remarked, “This is another success story for British science. It is a prime example of how we can harness artificial intelligence to innovate new treatments. Positive results have been achieved in the initial human trials, and this work will help accelerate the global delivery of vaccines.”